Sort
48,018 grants matching “immunotherapy”
Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer
$458,934Philip W Kantoff · Sloan-Kettering Inst Can Research · U01 · FY2017 · CA
T Cell Homeostasis
$458,912Stephen C Jameson · University Of Minnesota · R01 · FY2024 · AI
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment
$458,847E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2024 · NS
BBB Protection in HIV Infection: Barrier-shielding effects of PARP inhibition
$458,846Yuri Persidsky · Temple Univ Of The Commonwealth · R01 · FY2015 · MH
BBB Protection in HIV Infection: Barrier-shielding effects of PARP inhibition
$458,846Yuri Persidsky · Temple Univ Of The Commonwealth · R01 · FY2016 · MH
BBB Protection in HIV Infection: Barrier-shielding effects of PARP inhibition
$458,846Yuri Persidsky · Temple Univ Of The Commonwealth · R01 · FY2014 · MH
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
$458,810John H Sampson · Duke University · R01 · FY2011 · CA
PSMA-VRP vaccine for prostate cancer
$458,795William C Olson · Progenics Pharmaceuticals, Inc. · R44 · FY2007 · CA
Leveraging the metastatic tumor stroma to limit breast cancer progression
$458,795Sheila A Stewart · Washington University · R01 · FY2024 · CA
APOBEC3 Proteins in HIV Restriction
$458,762Reuben S Harris · University Of Minnesota · R37 · FY2021 · AI
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
$458,735Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2016 · CA
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
$458,731Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
$458,731Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA
An epigenomic approach to reactivate latent HIV
$458,687Qin Feng · University Of Houston · R33 · FY2020 · AI
Alternative MHCII Processing of Influenza Virus Proteins
$458,610Laurence Crane Eisenlohr · Thomas Jefferson University · R01 · FY2014 · AI
The role of Tumor associated macrophages in glioblastoma
$458,596Dolores Hambardzumyan · Emory University · R01 · FY2017 · NS
The role of Tumor associated macrophages in glioblastoma
$458,596Dolores Hambardzumyan · Emory University · R01 · FY2018 · NS
Relative Immunological Effectiveness (RIE) of Carbon Ion Radiation Therapy for Pancreatic Cancer
$458,589Chandan Guha · Albert Einstein College Of Medicine · R01 · FY2024 · CA
Cancer Immunotherapy Clinical Trials
$458,587Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$458,517Fox Chase Cancer Center · U10 · FY2000 · CA
Arginase positive monocyte mediated RGC neuroprotection after traumatic optic neuropathy
$458,517Andrew Robert Sas · Ohio State University · R01 · FY2024 · EY
Relative Immunological Effectiveness (RIE) of Carbon Ion Radiation Therapy for Pancreatic Cancer
$458,507Chandan Guha · Albert Einstein College Of Medicine · R01 · FY2025 · CA
DEVELOPMENTAL FUNDS
$458,402Michelle M Le Beau · University Of Chicago · P30 · FY2014 · CA
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$458,346Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2025 · CA
The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
$458,329Olivier Elemento · Weill Medical Coll Of Cornell Univ · U24 · FY2019 · CA